Reasons Industries to Thrive Post-Pandemic! Stem Cell Therapy for Osteoarthritis Market Report xyz Answers it Analysis by Key Companies Mesoblast,…

Global Coronavirus pandemic has impacted all industries across the globe, Stem Cell Therapy for Osteoarthritis market being no exception. As the global economy heads towards major recession post-2009 crisis, Cognitive Market Research has published a recent study which meticulously studies the impact of this crisis on Global Stem Cell Therapy for Osteoarthritis market and suggests possible measures to curtail them. This press release is a snapshot of the research study and further information can be gathered by accessing complete report.To Contact Research Advisor Mail us @ [emailprotected] or call us on +1-312-376-8303. As per the ongoing market, research finding says Stem Cell Therapy for Osteoarthritis Market is growing at a High CAGR during the forecast period 2020-2027. The increasing interest of the investors in the said market industry is one of the prominent reason for the growth and expansion of this market

The Stem Cell Therapy for Osteoarthritis Market research report 2020 give a detailed analysis of market and industry revenue (USD Mn) as well as volume (units) for year 2015-2027. The report provides updated information on market as well as future analysis regarding growth. Furthermore, Stem Cell Therapy for Osteoarthritis report quantifies the market share held by the significant players of the industry and gives an in-depth view of the competitive landscape.

Get A Free Sample of Stem Cell Therapy for Osteoarthritis Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-therapy-for-osteoarthritis-market-report#download_report

Major Key Players mentioned in the report are: Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics

Manufacturers are facing continued downward pressure on demand, production and revenues as the COVID-19 pandemic strengthens. Manufacturers should be prepared for major global supply chain disruptions. This will influence the OEMs, however, will likewise wave all through flexible chain, influencing manufactures by driving reduced demand for materials and parts. Thus, some of the key players are mainly focusing on research & development to provide innovative products to client. The competitive analysis is mentioned in detail which includes, profiling of all the major players involved in XXX market. For instance, company profiling includes business overview, product information, their R&D investment, key developments, business strategy and SWOT analysis. Additionally, market share of top companies is provided to give an all-inclusive view on competitive parameter.

The report has mentioned types and applications which will provide in-depth analysis of market to the users, enhancing understanding of the market. The study provides which type is accounted for the largest share with qualitative analysis. Global Stem Cell Therapy for Osteoarthritis Market Segmentation by Type: Monotherapy, Combination Therapy

Global Stem Cell Therapy for Osteoarthritis Market Segmentation by Applications: Osteoarthritis (unspecified), Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis

To get Detailed Overview (COVID-19 Impact Analysis): Click Here> Download Sample Report of Stem Cell Therapy for Osteoarthritis Market Report 2020 (Coronavirus effect on Stem Cell Therapy for Osteoarthritis Market)

Report additionally provides content related to the Corona outbreak, as it has greatly impacted global business and each and every sector. Thus, to make wise decisions related to business, understanding of current scenario of market is a crucial process. Our report helps users to take a holistic view of Stem Cell Therapy for Osteoarthritis Market after the impact of COVID 19. Based on the type and applications, introduction of new products and research involved in the development of new products is one of the major aspects which is likely to have an impact on the market. Similarly, the impact of the COVID-19 on the manufacturing and the effect of the demand for these products is also one of the major aspects which are likely to have an impact on the growth of the market in the estimated forecasts period.

Request Exclusive Free Sample [emailprotected] https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-therapy-for-osteoarthritis-market-report#download_report

The report also covers and analyses a detailed description of the regions. The report study determines and derives the market growth in these regions. In addition, this report also highlights the region with largest share and also, the fastest-growing regions in the estimated forecasts period. These are also used for the determination and development in these regions affecting the growth of the market in the estimated forecasts period.

To access detailed Research Methodology click here @ https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-therapy-for-osteoarthritis-market-report#download_report

This report on global Stem Cell Therapy for Osteoarthritis market is suitable for any stakeholders investing in the market. Moreover, report covers all the quantitative and qualitative study of the global Stem Cell Therapy for Osteoarthritis market on the basis past and current data. It also adds major driving factors that are responsible for the growth of market. Moreover, opportunities and threats to market are added by complete analysis of market. All the information is easily understandable due to graphs and pie charts wherever necessary.

Major Points of the Global Stem Cell Therapy for Osteoarthritis Report: All the market segmentation represented region wise Past, present, and future market size for the value and volume Market shares and business strategies of the key players Emerging all segments and regional markets The whole analysis of the XXX market Recommendations regarding business opportunities and current challenges Information regarding advanced development and technology innovation for the Stem Cell Therapy for Osteoarthritis market

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in an easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: [emailprotected] Web: https://www.cognitivemarketresearch.com/

Link:
Reasons Industries to Thrive Post-Pandemic! Stem Cell Therapy for Osteoarthritis Market Report xyz Answers it Analysis by Key Companies Mesoblast,...

Animal Stem Cell Therapy Market likely to touch new heights by end of forecast – News by aeresearch

N95 Respirator Mask Industry Market Competitive Landscape Analysis, Major Regions, Report 2020-2025 By Market Study Report

Global N95 Respirator Mask Industry Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to cover the authenticate information of the market size, share, product footprint, reven...

Global Ginkgo Biloba Extract Industry Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to cover the authenticate information of the market size, share, product footprint, rev...

Global Radiosurgical System Industry Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to cover the authenticate information of the market size, share, product footprint, reve...

Global Monopolar Forceps Industry Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to cover the authenticate information of the market size, share, product footprint, revenue...

The Resveratrol market report offers an all-inclusive analysis of this industry vertical with emphasis on the key growth drivers, limitations, and opportunities shaping the market dynamics in the upcoming years. As per the report, the market is pro...

Read more from the original source:
Animal Stem Cell Therapy Market likely to touch new heights by end of forecast - News by aeresearch

Male Pattern Baldness gets longer effect QR678 therapy, more effective than Platelet-Rich Plasma (PRP): Journal of Cosmetic Dermatology Published…

(Eds: Disclaimer: The following content is a press release. PTI takes no editorial responsibility for the same.) Mumbai, 8th September 2020: QR 678, a patented treatment for hair regrowth therapy for men and women, has proven to be more effective than PRP as a hair loss treatment. This study was published in an iconic and much respected American Journal called the Journal of Cosmetic Dermatology. It showed that as compared to the Platelet Rich Plasma (PRP) therapy, QR 678showed significant improvement in hair regrowth with almost 100% reduction in hair fall. QR 678 was invented by Dr.Debraj Shome and Dr.Rinky Kapoor, celebrity cosmetic surgeons from India. They observed that male pattern baldness, known as Androgenic Alopecia characterised by progressive hair loss in men growing at a rampant rate of 58% in males aged 30-50 years which initiated their urge to research and find a solution to this cosmetic issue leading to the invention of QR 678. The therapy curbs hair fall and increases the thickness, the number and density of existing hair follicles, offering greaterhair coverage to the ones with alopecia.The formulation has received patents in the United States and in India. Dr.Debraj Shome, Cosmetic Surgeon and Director, at The Esthetic Clinics, said, The hair-regrowth treatments available currently have many limitations; they cannot revive hair beyond a certain stage. QR678 is a process where growth factors are injected in the hair follicles, which not only arrests hair fall but also stimulates hair growth. QR678 is a non-surgical, pain-free and non-invasive procedure for the hair regrowth treatment which has shown very good results in over 10,000 patients. Practicing from the Esthetics Clinics, Dr Shome says that, from my experience as a cosmetic surgeon dealing with hair loss patients on a daily basis the treatment has responded very well, especially in India. QR 678 has had a success rate of 90% in India and this is the highest success rate achieved by any hair fall treatment in a shortest treatment time of 6-8 sessions. Comparing the two treatments in question, Dr. Rinky Kapoor partner to Dr Shome and one of leading Dermatologists in India adds, PRP is used by all Dermatologists and plastic surgeons for hair growth. PRP involves extracting platelets from human blood and injecting it into the scalp to cause hair growth. But, the truth of the matter is that this therapy is more based on hope than actual science. There has never been a randomised controlled trial showing that PRP actually causes hair growth. That is why we conducted a comparative trial between the QR678 and PRP treatments and no surprises that the QR678 treatment caused almost 300% better results than the PRP". The trial was a split head trial, comparing the PRP treatment efficacy with the QR678 treatments. While PRP is supposed to have growth factors for hair growth, the QR 678 treatment is a bioengineered, first in class hair therapy, with six hair growth factors and biomimetic peptides, administered to the scalp via mesotherapy. With Alopecia and hair loss becoming more and more common and affecting more than 40% males and 30% Females over the age of 30 globally, having a new age, proven therapy is very important for the world. More than 12000 patients have already experienced amazing results with the QR 678 treatment, which has an USA and an Indian patent and is now being exported to multiple countries from India. Dr. Kapoor says, "We, as Doctors need to decide whether the treatments we offer are indeed backed by science or not. Just because hair loss is so common and we didn''t have too many solutions prior to the QR678 doesn''t mean that we use treatments like the PRP which have no strong evidence based data for hair growth. Ultimately, science must win!" The acceptance of the Journal of Cosmetic Dermatology of the QR678 hair growth treatment will change the execution and delivery of hair loss treatment, as PRP was rampantly and randomly used by dermatologists, plastic surgeons and cosmetic surgeons alike, in India and globally. India through the ''Made in India'' top class hair innovation the QR678, may have pioneered a way forward for cosmetology at an international level. Dr.Debraj Shome has been a global pioneer in developing new techniques and solutions for facial plastic surgery and facial cosmetic surgery for more than a decade, he is amongst the few super specialists India has in this area of cosmetology. Dr. Shome is also a celebrated, best-selling, and internationally acclaimed author of Dear People, With Love & Care, Your Doctors. Maintained its position as a bestseller for weeks in a row this book is an anthology of short stories based on the real-life doctor-patient relationship. He has written more than 50 peer-reviewed international papers in top International research journals. Dr. Shome is also the patent holder for the invention of the QR678 hair growth factor injections. This hair growth formulation has received patents in multiple locations, including the USA and India. Dr.Rinky Kapoor is one of the best dermatologists in India today. She is also an expert in the field of non-invasive and non-surgical skin rejuvenation treatments. She has a unique ability to use a mixture of treatments for correct results making her the one of the finest dermatologist in India.What sets Dr Rinky Kapoor apart is the fact that she uses the world''s best and latest technological advances to give the most natural looking results. She says, Its the joy of seeing the look of wonder and contentment on the faces of my patients and this is what keeps me going daily. About The Esthetic Clinics: (https://www.theestheticclinic.com/) The Esthetic Clinics is a group of world-class centresdedicated to plastic surgery & skin care. They are currently located at Mumbai, New Delhi, Ahmedabad, Hyderabad, Bangalore and Kolkata in India. The Esthetic Clinics practice evidence-based medicine and perform cosmetic surgery for beauty, plastic surgery for birth abnormalities; plastic surgery for fractures, trauma & cancer induced facial deformities. They also provide laser surgery & many cosmetic solutions for many skin diseases. The Esthetic Clinicswas voted as the Most Promising & Innovative Cosmetic Clinics 2016 at the Pharma Leaders Summit & Awards 2016. The Esthetic Clinics was rated by the Times Health Survey 2019 as being one of the Top Clinics in Plastic Surgery & Cosmetic Surgery, Dermatology & Trichology, in Mumbai, India. PWR PWR Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI More from Outlook Magazine

Read this article:
Male Pattern Baldness gets longer effect QR678 therapy, more effective than Platelet-Rich Plasma (PRP): Journal of Cosmetic Dermatology Published...

Transcriptional Regulation in Embryonic Stem Cells …

Abstract

Transcriptional regulation is a pivotal process that confers cellular identity and modulates the biological activities within a cell. In embryonic stem cells (ESCs), the intricate interplay between transcription factors and their targets on the genomic template serves as building blocks for the transcriptional network that governs self-renewal and pluripotency. At the heart of this complex network is the transcription factor trio, Oct4, Sox2 and Nanog, which constitute the ESC transcriptional core. Regulatory mechanisms such as autoregulatory and feedforward loops support the ESC transcriptional framework and serve as homeostatic control for ESC maintenance. Large-scale studies such as loss of function RNAi screens and transcriptome analysis have led to the identification of more players that support pluripotency. In addition, genome-wide localization studies of transcription factors have further unraveled the interconnectivity within the ESC transcriptional circuitry. Transcription factors also work in concert with epigenetic factors and together, this crosstalk between transcriptional and epigenetic regulation maintains the homeostasis of ESC. This chapter provides an overview of the significance of transcriptional regulation in ESC and traces the recent advances made in dissecting the ESC transcriptional regulatory network.

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content,

to check access.

Unable to display preview.Download preview PDF.

1.

Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860921.

2.

Johnson KM, Mitsouras K, Carey M. Eukaryotic transcription: the core of eukaryotic gene activation. Curr Biol 2001; 11:R5103.

3.

Levine M, Tjian R. Transcription regulation and animal diversity. Nature 2003; 424:14751.

4.

Pesce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 2001; 19:2718.

5.

Nichols J, Zevnik B, Anastassiadis K et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95:37991.

6.

Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000; 24:3726.

7.

Niwa H, Toyooka Y, Shimosato D et al. Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation. Cell 2005; 123:91729.

8.

Avilion AA, Nicolis SK, Pevny LH et al. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17:12640.

9.

Masui S, Nakatake Y, Toyooka Y et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 2007; 9:62535.

10.

Kopp JL, Ormsbee BD, Desler M et al. Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 2008; 26:903911.

11.

Rodda DJ, Chew JL, Lim LH et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 2005; 280:247317.

12.

Kuroda T, Tada M, Kubota H et al. Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol 2005; 25:247585.

13.

Ambrosetti DC, Scholer HR, Dailey L et al. Modulation of the activity of multiple transcriptional activation domains by the DNA binding domains mediates the synergistic action of Sox2 and Oct-3 on the fibroblast growth factor-4 enhancer. J Biol Chem 2000; 275:2338797.

14.

Ambrosetti DC, Basilico C, Dailey L. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Mol Cell Biol 1997; 17:63219.

15.

Botquin V, Hess H, Fuhrmann G et al. New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. Genes Dev 1998; 12:207390.

16.

Nishimoto M, Fukushima A, Okuda A et al. The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. Mol Cell Biol 1999; 19:545365.

17.

Yuan H, Corbi N, Basilico C et al. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev 1995; 9:263545.

18.

Chew JL, Loh YH, Zhang W et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/ Sox2 complex in embryonic stem cells. Mol Cell Biol 2005; 25:603146.

19.

Okumura-Nakanishi S, Saito M, Niwa H et al. Oct-3/4 and Sox2 Regulate Oct-3/4 Gene in Embryonic Stem Cells. J Biol Chem 2005; 280:53075317.

20.

Remenyi A, Lins K, Nissen LJ et al. Crystal structure of a POU/HMG/DNA ternary complex suggests differential assembly of Oct4 and Sox2 on two enhancers. Genes Dev 2003; 17:204859.

21.

Williams DC, Jr., Cai M, Clore GM. Molecular basis for synergistic transcriptional activation by Oct1 and Sox2 revealed from the solution structure of the 42-kDa Oct1.Sox2.Hoxb1-DNA ternary transcription factor complex. J Biol Chem 2004; 279:144957.

22.

Maruyama M, Ichisaka T, Nakagawa M et al. Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells. J Biol Chem 2005; 280:2437124379.

23.

Mullin N P, Yates A, Rowe AJ et al. The pluripotency rheostat Nanog functions as a dimer. Biochem J 2008; 227231.

24.

Wang W, Lin C, Lu D et al. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci USA 2008; 105:92905.

25.

Chambers I, Colby D, Robertson M et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113:64355.

26.

Mitsui K, Tokuzawa Y, Itoh H et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113:63142.

27.

Ivanova N, Dobrin R, Lu R et al. Dissecting self-renewal in stem cells with RNA interference. Nature 2006; 442:5338.

28.

Loh YH, Wu Q, Chew JL et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006; 38:43140.

29.

Chambers I, Silva J, Colby D et al. Nanog safeguards pluripotency and mediates germline development. Nature 2007; 450:12304.

30.

Niwa H, Ogawa K, Shimosato D et al. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 2009; 460:11822.

31.

Kalmar T, Lim C, Hayward P et al. Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. PLoS Biol 2009; 7:e1000149.

32.

Carter MG, Stagg CA, Falco G et al. An in situ hybridization-based screen for heterogeneously expressed genes in mouse ES cells. Gene Expr Patterns 2008; 8:18198.

33.

Silva J, Nichols J, Theunissen TW et al. Nanog is the gateway to the pluripotent ground state. Cell 2009; 138:72237.

34.

Jiang J, Chan YS, Loh YH et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol 2008; 10:35360.

35.

Hall J, Guo G, Wray J et al. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. Cell Stem Cell 2009; 5:597609.

36.

Ema M, Mori D, Niwa H et al. Kruppel-like factor 5 is essential for blastocyst development and the normal self-renewal of mouse ESCs. Cell Stem Cell 2008; 3:55567.

37.

Dejosez M, Krumenacker JS, Zitur LJ et al. Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. Cell 2008; 133:116274.

38.

Hu G, Kim J, Xu Q et al. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev 2009; 23:83748.

39.

Ding L, Paszkowski-Rogacz M, Nitzsche A et al. A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity. Cell Stem Cell 2009; 4:40315.

40.

Gaspar-Maia A, Alajem A, Polesso F et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 2009; 460:8638.

41.

Wang J, Rao S, Chu J et al. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006; 444:3648.

42.

Wu Q, Chen X, Zhang J et al. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem 2006; 281:240904.

43.

Suzuki A, Raya A, Kawakami Y et al. Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. Proc Natl Acad Sci USA 2006; 103:102949.

44.

Torres J, Watt FM. Nanog maintains pluripotency of mouse embryonic stem cells by inhibiting NFkappaB and cooperating with Stat3. Nat Cell Biol 2008; 10:194201.

45.

Araki R, Fukumura R, Sasaki N et al. More than 40,000 transcripts, including novel and noncoding transcripts, in mouse embryonic stem cells. Stem Cells 2006; 24:25228.

46.

Sharov AA, Piao Y, Matoba R et al. Transcriptome analysis of mouse stem cells and early embryos. PLoS Biol 2003; 1:E74.

47.

Nagalakshmi U, Wang Z, Waern K et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 2008; 320:13449.

More here:
Transcriptional Regulation in Embryonic Stem Cells ...

Global Cell Isolation Market Report Promising Growth of CAGR of 17.91% , Analysis of Top companies and their Share, Size,Scope and Current Trends -…

GlobalCell Isolation Marketreport would come in handy to understand your competitors and give you an insight into sales; volumes, revenues in the Cell Isolation industry, assists in making strategic decisions. Cell Isolation Market is expected to grow at a CAGR of 17.91% from 2020 to 2023 and explains why and how it is going to achieve this growth.It provides vital information on every parameter which is required for making strategic decisions and development of every business in the industry.

Request a Sample Copy of the Report For COVID-19 Impact Analysis onCell Isolation Market

About Cell Isolation Market The rise in demand for clinical diagnosis is one of the key factors anticipated to drive the cell isolation market growth during the forecast period. To effectively treat various diseases using genetic engineering tools, early diagnosis is essential. Genetic engineering tools provide diagnostic enzymes such as cholesterol oxidase and xylitol oxidase. These diagnostic enzymes identify specific cells like cells with high levels of cholesterol. When blood levels of these particular enzymes increase significantly, it indicates a probable site for tissue damage, which releases these enzymes in the blood. These enzymes are used in assays using samples of serum or urine. The isolation of these enzymes can provide the required enzymes for clinical diagnosis. Thus, genetic engineering tools are useful, precise, and economical for researchers and healthcare providers to diagnose patients. Research analysts have predicted that the cell isolation market will register a CAGR of almost 19% by 2023.

TheTop Manufacturers/playersincluding:-

Agilent Technologies Inc., Becton Dickinson and Co., Merck KGaA, QIAGEN NV, Thermo Fisher Scientific Inc.

Get a Sample PDF of report https://www.360marketupdates.com/enquiry/request-sample/14035352

Market Segment of Cell Isolation Industry:

Market Overview

Competitive Landscape

Feel Free to Ask Question Before Purchasing the Report at https://www.360marketupdates.com/enquiry/pre-order-enquiry/14035352

Cell Isolation Market Report provides comprehensive analysis of-

Key Summary of Cell Isolation Market Growth Report:

In our market size and forecast determination efforts, in-depth secondary research was initially completed to realize an honest perspective of the market in each region. Extensive primary research was also administered by interviewing key executives from the industry. These interviews helped us to fill-in the info gaps after secondary research. Several secondary sources like encyclopedia, directories, and databases are wont to identify and collect information useful for this extensive techno-commercial study.

Key Questions Answered in ROY Cell Isolation Market Report:

Purchase this report (Price2500 USD for a single-user license)@ https://www.360marketupdates.com/purchase/14035352

In the end, the Cell Isolation Market report makes some important proposals for a new project of the Cell Isolation Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of Global Cell Isolation Industry covering all important parameters.

Table of Contents included in Cell Isolation Market ROY Report

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by end-user industry

PART 07: Market segmentation by application

PART 08: Geographical Segmentation

PART 09: A Decision framework

PART 10: Impact of drivers and challengesAnd Many More Parts Covered.

Be sure to follow on Linkedin at @360 Market Updatesfor more on growth research and the research market.

CONTACT US

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +1 424 253 0807 / + 44 203 239 8187

OUR OTHER REPORTS:

TV Wall Market 2020 Recent Development and its impact on Market Share, Size, Sale, Growth Rate and Future Opportunity

Immunoassay Analyzers Market 2020 Recent Development and its impact on Market Share, Size, Sale, Growth Rate and Future Opportunity

Tetramethyl Orthosilicate (CAS 681-84-5) Market Report 2020 Indepth Analysis on Market Share, Size, Growth Rate and Factors, Future Developments and Prospects

Digital Education Projector Market 2020 Recent Development and its impact on Market Share, Size, Sale, Growth Rate and Future Opportunity

Aerospace Fabrics Market 2020 Global Industry Growth Rate, Share, Size, Price, Prospect, Developments and Forecast till 2025

More here:
Global Cell Isolation Market Report Promising Growth of CAGR of 17.91% , Analysis of Top companies and their Share, Size,Scope and Current Trends -...

Menkes SyndromeIndustry 2020 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces…

Data Bridge Market Research recently introducedGlobal Menkes Syndrome Market Size, Industry Share, Growth, Industry Trends and Forecast To 2020study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2020.Menkes Syndrome Industry 2020 GlobalMarket Research report 2020 covers a detailed study of the Menkes Syndrome Market size, growth, and share, trends, consumption, segments, application and Forecast 2020. The study objective of this report is to analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. The market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa are kept into focus while creating this global Menkes Syndrome market report. The growth of the Menkes Syndrome market was mainly driven by the increasing R&D spending across the world, howeverlatest COVID scenarioand economic slowdown have changed complete market dynamics.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-menkes-syndrome-market

KNOW YOUR OPTIONS IN THE FIGHT AGAINST COVID-19

The COVID-19 Pandemic has created bottlenecks across industry pipelines, sales funnels, and supply chain activities. This has created unprecedented budget pressure on company spending for industry leaders. This has increased requirement for opportunity analysis, price trend knowledge and competitive outcomes. Use the DBMR team to create new sales channels and capture new markets previously unknown. DBMR helps its clients to grow in these uncertain markets.

Prominent Players Operating In The Market Include:-Fortress Biotech, Teva Pharmaceutical Industries Ltd, Amerigen Pharmaceuticals Limited, Mylan N.V., Bausch Health, H. Lundbeck A/S and others.

The Menkes Syndrome market accounted to USD 17.26 Billion in 2016 growing at a CAGR of 8.1% during the forecast period of 2019 to 2024.

Market Definition: Menkes Syndrome Market-Menkes syndrome is also known as steely hair disease is a rare, X-linked genetic disorder of copper metabolism caused by gene mutations of copper transporter ATP7A.Because of the mutation in copper transport gene, copper is unavailable to reach to the various cells where it is essential for the structure and function of various enzymes. It is characterized by sparse, kinky hair, failure to thrive and progressive deterioration of the nervous system.

According to the statistics published by National Organization for Rare Disorders, Inc, an estimated population of Menkes syndrome is about 1 in 100,000-250,000 live birth. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Browse Full Report with Details TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-menkes-syndrome-market

ThisMenkes Syndrome Marketreport provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

Browse 60 Market Data Tables and 220 Figures spread through 320 Pages and in-depth TOC on Menkes Syndrome Market .

Menkes Syndrome Marketis highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Menkes Syndrome Market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

For More Information or Query or Customization Before Buying, Visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-menkes-syndrome-market

Global Menkes Syndrome Market Segmented ByType (Neurodegenerative Disease, X-linked Copper Malabsorption)

Global Menkes Syndrome Market Segmented byDistribution Channel (Hospital Pharmacies, Retail Pharmacies)

Global Menkes Syndrome Market SegmentedBy Therapy Type (Gene Therapy, Copper Injection Therapy), Drugs (Penicillamine, Droxidopa and Others),

Global Menkes Syndrome Market Segmented ByRoute of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics and Others)

Some Of The Major Players Operating In The Menkes Syndrome Market AreFortress Biotech, Teva Pharmaceutical Industries Ltd, Amerigen Pharmaceuticals Limited, Mylan N.V., Bausch Health, H. Lundbeck A/S and others.

Key Questions Answered in Menkes Syndrome Market Report:-

What Our Report Offers:

The Menkes Syndrome report has been produced with the systematic gathering and analysis of information about individuals or organizations conducted through social and opinion research. With the studies, insights and analysis mentioned in the report, you get comprehensible idea about the marketplace with which you can take business decisions quickly and easily. The worldwide Menkes Syndrome advertise report comprises of all the organization profiles of the key players and brands. Market definition covered in this Menkes Syndrome report studies the market drivers and market restraints with which businesses can get idea of whether to increase or decrease the production of a particular product.

Detailed TOC of Menkes Syndrome Market Research Report: Table of Contents

1 Introduction

2Market Segmentation

3 Market Overview

4 Executive Summaries

5 Premium Insights

6 Regulatory Procedure

7 Menkes Syndrome Market, By Type

8 Menkes Syndrome Market, by disease type

9 Menkes Syndrome Market, By Deployment

10 Menkes Syndrome Market, By End User

11 Menkes Syndrome Market, By Distribution Channel

12 Menkes Syndrome Market, By Geography

13 Menkes Syndrome Market, Company Landscape

14 Company Profile

Continued!!!

To Gain More Insights into the Market with Detailed Table of Content and Figures, Click here-https://www.databridgemarketresearch.com/toc/?dbmr=global-menkes-syndrome-market

We can also customize this report and provide individual chapters or a region-wise breakdown report such as North America, Europe or Asia. Also, if you have any special requirements, ([emailprotected]) please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 819+2 7475

Email:[emailprotected]+

Originally posted here:
Menkes SyndromeIndustry 2020 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces...

Global Organoids and Spheroids Market Is Expected to Reach USD 2794.79 Million by 2027 : Fior Markets – GlobeNewswire

September 08, 2020 16:00 ET | Source: Fior Markets

Newark, NJ, Sept. 08, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global organoids and spheroids market is expected to grow from USD 502.92 million in 2019 and to reach USD 2794.79 million by 2027, growing at a CAGR of 23.91 % during the forecast period 2020-2027.

The growing prevalence of chronic disorders in recent times has increased the demand for effective drugs. The organoids and spheroids model is increasingly becoming popular as they provide a better perspective for human developmental biology research. The organoids model reveals the effects of covid-19 on several intestinal cells. Thus, these models are playing a significant role in the vaccine development process. The rise in demand for diagnostics and therapeutics solutions for these chronic diseases is fuelling market growth.

The organoids and spheroids are the three-dimensional structures that replicate the condition of different tissues present in the human body. The organoids model works as an in-vitro model for the study of biological development. The organoids can be established for organs such as kidney, retina, brain, liver, small and large intestine, lungs, etc. The organoids can be derived from a single adult stem cell or the embryonic stem cell. On the other hand, spheroids consist of a cluster of cells. These are derived from both the single-cell type and multi-cellular stems. The organoids and spheroids differ in the driving force required for the development. The organoids are formed by internal development processes and spheroids forms by adhesion of cells to each other. These also differ in the time duration for which the 3D culture can be maintained.

The human organoids have helped in the analysis of many tissues, which helps in a better understanding of the working of the organs. The 3D models of human organs have opened up opportunities for conducting various studies and experiments to analyze the effects of drugs on different organs. It also has provided potential ways of organ transplantation. Further, the growing technological advancements in the spheroid and organoid 3D models are fuelling the market growth. Apart from this, the major players operating in the market are also focusing on facilitating cell activities by taking control of the microenvironment of the culture.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418832/request-sample

Key players operating in the organoids and spheroids market are 3D Biotek LLC, 3D Biomatrix, ATCC, Cellesce Ltd., Hubrecht Organoid Technology (HUB), Merck KGaA, STEMCELL Technologies Inc., Corning Incorporated, AMS Biotechnology Limited, Perkin Elmer, Kuraray, Thermo Fisher Scientific, Inc., Greiner Bio-One, Prellis Biologics, Lonza and others. The major players in the organoids and spheroids market are focusing on expansionary strategies such as mergers & acquisitions, recent developments, joint ventures, collaborations, product innovations and partnerships. These strategies would extract higher market shares for the players and thus strengthen their position in the global market. Thermo Fisher Scientific and Corning Incorporated are some of the biggest manufacturers and suppliers of organoids and spheroids in the global market.

Spheroids segment dominated the market and held the largest market share of 54.92% in the year 2019

On the basis of type segment, the global organoids and spheroids market includes organoids and spheroids. The organoids are segmented into product type, techniques and source. The product type of organoids includes neural organoids, intestinal organoids, hepatic organoids and others. The techniques include crypt organoid culture techniques, general submerged technique, clonal organoid from Lgr5+ cells, air-liquid interface (ALI) method and brain and retina organoid formation protocol. The sources segment includes primary tissues and stem cells. The spheroids are also segmented into product type, techniques and source. The product type of spheroids includes mammospheres, neurospheres, embryoid bodies, multi-cellular tumor spheroids and hepatospheres. The techniques segment includes hanging drop method, micropatterned plates, low cell attachment plates and others. The source of spheroid includes primary cells, cell line and iPSCs derived cells. Spheroids dominated the market and held the largest market share of 54.92% in the year 2019. The spheroids are in high demand owing to its increased application in cancer research and drug discovery. The spheroids can be cultured to produce cells of consistent shape, which can be used for thorough analysis. Further, the organoids segment is projected to register an impressive growth rate as these are used as in-vitro models in the process of drug discovery. The segment is expected to be driven by the intestinal organoids type owing to the increased application is cell biology and disease modeling.

Developmental biology segment dominated the market and held the largest market share of 28.65% in the year 2019

On the basis of the application segment, the global organoids and spheroids market includes personalized medicine, developmental biology, drug toxicity and efficacy testing, disease pathology testing and regenerative medicine. Developmental biology dominated the market and held the largest market share of 28.65% in the year 2019. The organoids which are derived from induced pluripotent stem cells and embryonic stem cells are useful in human developmental biology. The spheroids and organoids have been increasingly used in the development biology study of the pancreas, kidney, stomach, liver, etc. for the purpose of embryonic development, tissue homeostasis and lineage specification.

Biotechnology and pharmaceutical companies segment dominated the market and held the largest market share of 39.82% in the year 2019

The end-user segment includes academic and research institutes, hospitals and diagnostic centers and biotechnology and pharmaceutical companies. Biotechnology and pharmaceutical companies segment dominated the market and held the largest market share of 39.82% in the year 2019. The organoids and spheroids are mainly used in clinical applications owing to the vast scope of the experiment. Thus, the biotechnology and pharmaceutical companies are using these increasingly in the drug discovery processes.

Browse full report with TOC athttps://www.fiormarkets.com/report/organoids-and-spheroids-market-by-type-organoids-and-418832.html

Regional Segment Analysis of the Organoids and Spheroids Market

On the basis of geography, the global organoids and spheroids market is classified into North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America region accounted for a significant market share of 43.02% in the year 2019. The region has been lately, investing in the organoid and spheroids based research models. Further, the growing technological advancements provides a platform for extensive research on 3D models of human tissue structure for the development of personalized and regenerative medicines. However, Asia-Pacific is expected to register the highest growth rate during the forecast period. The growing patient population owing to the prevalence of chronic diseases has led to the development of the market in the region. Further, the growth of stem cell research has increased the demand for organoids and spheroids.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418832

About the report:

The global organoids and spheroids market is analyzed on the basis of value (USD Million). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418832&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.marketquest.biz

Related Reports Hydroxychloroquine Market - https://www.fiormarkets.com/report/hydroxychloroquine-market-by-dosage-type-200-mg-400-417942.html Immunotherapy Drugs Market - https://www.fiormarkets.com/report/immunotherapy-drugs-market-by-drug-type-checkpoint-inhibitors-417899.html Bovine Lactoferrin Market - https://www.fiormarkets.com/report/bovine-lactoferrin-market-by-type-freeze-dried-and-milled-417794.html CBD Hemp Oil Market - https://www.fiormarkets.com/report/cbd-hemp-oil-market-by-type-pure-cbd-411566.html

View original post here:
Global Organoids and Spheroids Market Is Expected to Reach USD 2794.79 Million by 2027 : Fior Markets - GlobeNewswire

School of Science grows by 10 – MIT News

Despite the upheaval caused by the coronavirus pandemic, 10 new faculty members have joined MIT in the departments of Biology; Chemistry; Earth, Atmospheric and Planetary Sciences; Mathematics; and Physics. The School of Science welcomes these new faculty, most of whom began their appointment July 1, amidst efforts to update education and research plans for the fall semester. They bring exciting and valuable new areas of strength and expertise to the Institute.

Camilla Cattania is an earthquake scientist. She uses continuum mechanics, numerical simulations, and statistics to study fault mechanics and earthquake physics at different scales, from small repeating events to fault interaction on regional and global scales. The models she has developed can help forecast earthquake sequences caused by seismic or aseismic events, such as aftershocks and swarms induced by forcing mechanisms like magma moving under the Earths surface. She has also developed theoretical models to explain why certain faults rupture in predictable patterns while others do not. Cattanias research plans include widening her focus to other tectonic settings and geometrically complex fault structures.

Cattania earned her bachelors and masters degrees from Cambridge University in experimental and theoretical physics in 2011, after which she completed a PhD in Germany at the GFZ German Research Center for Geosciences and the University of Potsdam in 2015. Subsequently, she spent a few months as a researcher at Woods Hole Oceanographic Institution and as a postdoc at Stanford University and her doctoral institution. She joins the Department of Earth, Atmospheric and Planetary Sciences as an assistant professor.

Richard Fletcher researches quantum physics using atomic vapors one-millionth the density of air and one-millionth the temperature of deep space. By manipulating the gas with intricately sculpted laser beams and magnetic fields, he can engineer custom-made quantum worlds, which provide both a powerful test bed for theory and a wonderful playground for discovering new phenomena. The goal is to understand how interesting collective behaviors emerge from the underlying microscopic complexity of many interacting particles. Fletchers interests include superfluidity in two-dimensional gases, methods to probe the correlations between individual atoms, and how the interplay of interactions and magnetic fields leads to novel physics.

Fletcher is a graduate of Cambridge University, where he completed his bachelor's in 2010. Before returning to Cambridge University to earn his PhD in 2015, he was a research fellow at Harvard University. He originally came to MIT as a postdoc in 2016 and now joins the Department of Physics as an assistant professor. Fletcher is a member of the MIT-Harvard Center for Ultracold Atoms.

William Frank investigates deformation of the Earths crust. He combines seismology and geodesy to explore the physical mechanisms that control the broad continuum of rupture modes and fault instabilities within the Earth. His research has illuminated the cascading rupture dynamics of slow fault slip and how the aftershocks that follow a large earthquake can reveal the underlying behavior of the host fault. Frank considers shallow shifts that cause earthquakes down to deep creep that is all-but-invisible at the surface. His insights work to improve estimates of seismic hazards induced by tectonic dynamics, volcanic processes, and human activity, which can then inform risk prediction and mitigation.

Frank holds a bachelors degree from the University of Michigan in earth systems science, which he received in 2009. The Institut de Physique du Globe de Paris awarded him a masters degree in geophysics in 2011 and a PhD in 2014. He first joined MIT as a postdoc in 2015 before moving to the University of Southern California as an assistant professor in 2018. He now returns as an assistant professor in the Department of Earth, Atmospheric and Planetary Sciences.

Ronald Fernando Garcia Ruizadvances research on fundamental physics and nuclear structure largely through the development of novel laser spectroscopy techniques. He investigates the properties of subatomic particles using atoms and molecules made up of short-lived radioactive nuclei. Garcia Ruizs experimental work provides unique information about the fundamental forces of nature and offers new opportunities in the search beyond the Standard Model of particle physics. His previous research at CERN focused on the study of the emergence of nuclear phenomena and the properties of nuclear matter at the limits of existence.

Garcia Ruizs bachelors degree in physics was achieved in 2009 at Universidad Nacional de Colombia. After earning a masters in physics in 2011 at Universidad Nacional Autnoma de Mxico, he completed a doctoral degree in radiation and nuclear physics at KU Leuven in 2015. Prior to joining MIT, he was first a research associate at the University of Manchester from 2016-17 and then a research fellow at CERN. Garcia Ruiz has now joined the Department of Physics as an assistant professor. He began his appointment Jan. 1. He is also affiliated with the Laboratory for Nuclear Science.

Ruth Lehmann studies germ cells. The only cells in the body capable of producing an entire organism on their own, germ cells pass genomic information from one generation to the next via egg cells. By analyzing the organization of their informational material as well as the mechanics they regulate, such as the production of eggs and sperm, Lehmann hopes to expose germ cells unique ability to enable procreation. Her work in cellular and developmental biology is renowned for identifying how germ cells migrate and lead to the continuation of life. An advocate for fundamental research in science, Lehmann studies fruit flies as a model to unveil vital aspects of early embryonic development that have important implications for stem cell research, lipid biology, and DNA repair.

Lehmann earned her bachelors degree in biology from the University of Tubingen in Germany. She took an interlude from her education to carry out research at the University of Washington in the United States before returning to Germany. There, she earned a masters equivalent from the University of Freiburg and a PhD from the University of Tubingen. Lehmann was subsequently a postdoc at the Medical Research Council Laboratory of Molecular Biology in the UK, after which she joined MIT. A faculty member and Whitehead Institute for Biomedical Research member from 1988 to 1996, she now returns after 23 years at New York University. Lehmann joins as a full professor in the Department of Biology and is the new director of the Whitehead Institute forBiomedical Research.

As an astrochemist, Brett McGuire is interested in the chemical origins of life and its evolution. He combines physical chemistry experiments and analyses with molecular spectroscopy in a lab, the results of which he then compares against astrophysics observation. His work ties together questions about the formation of planets and a planets ability to host and create life. McGuire does this by investigating the generation, presence, and fate of new molecules in space, which is vast and mostly empty, providing unique physical challenges on top of chemical specifications that can impact molecular formation. He has discovered several complex molecules already, including benzonitrile, a marker of carbon-based reactions occurring in an interstellar medium.

McGuires BS degree was awarded by the University of Illinois at Urbana-Champaign in 2009. He completed a masters in physical chemistry in 2011 at Emory University and a PhD in 2015 at Caltech. He then pursued a postdoc at the National Radio Astronomy Observatory and the Harvard-Smithsonian Center for Astrophysics. He joins the Department of Chemistry as an assistant professor.

Dor Minzer works in the fields of mathematics and theoretical computer science. His interests revolve around computational complexity theory, or more explicitly probabilistically checkable proofs, Boolean function analysis, and combinatorics. With collaborators, he has proved the 2-to-2 Games Conjecture, a central problem in complexity theory closely related to the Unique-Games Conjecture. This work significantly advances our understanding of approximation problems and, in particular, our ability to draw the border between computationally feasible and infeasible approximation problems.

Minzer is not new to online education. After earning his bachelors degree in mathematics in 2014 and a PhD in 2018, both from Tel-Aviv University, he became a postdoc at the Institute for Advanced Study in Princeton, New Jersey. He joins the Department of Mathematics as an assistant professor.

Lisa Piccirillo is a mathematician specializing in the study of three- and four-dimensional spaces. Her work in four-manifold topology has surprising applications to the study of mathematical knots. Perhaps most notably, Piccirillo proved that the Conway knot is not "slice." For all other small knots, "sliceness" is readily determined, but this particular knot had remained a mystery since John Conway presented it in the mid-1900s. After hearing about the problem at a conference, Piccirillo took only a week to formulate a proof. She is broadly interested in low-dimensional topology and knot theory, and employs constructive techniques in four-manifolds.

Piccirillo earned her BS in mathematics in 2013 from Boston College. Her PhD in mathematics was earned from the University of Texas at Austin in 2019, and from 2019-20 she was a postdoc at Brandeis University. She joins the Department of Mathematics as an assistant professor.

Jonathan Weissmans research interest is protein folding and structure, an integral function of life. His purview encompasses the expression of human genes and the lineage of cells, as well as protein misfolding, which can cause diseases and other physiological issues. He has made discoveries surrounding protein folding mechanisms, the development of CRISPR gene-editing tools, and other new therapeutics and drugs, and in the process generated innovative experimental and analytical methods and technologies. One of his novel methods is the ribosome profiling approach, which allows researchers to observe in vivo molecular translation, the process by which a protein is created according to code provided by RNA, a major advancement for health care.

Weissman earned a bachelors degree in physics from Harvard University in 1998 and a PhD from MIT in 1993. After completing his doctoral degree, he left MIT to become a postdoc at Yale University for three years, and then a faculty member at the University of California at San Francisco in 1996. He returns to MIT to join the Department of Biology as a full professor and a member of the Whitehead Institute for Biomedical Research. He is also a Howard Hughes Medical Institute investigator.

Yukiko Yamashita, a stem cell biologist, delves into the origins of multicellular organisms, asking questions about how genetic information is passed from one generation to the next, essentially in perpetuity, via germ cells (eggs and sperm), and how a single cell (fertilized egg) becomes an organism containing many different types of cells. The results of her work on stem cell division and gene transmission has implications for medicine and long-term human health. Using fruit flies as a model in the lab, she has revealed new areas of knowledge. For example, Yamashita has identified the mechanisms that enable a stem cell to produce two daughter cells with distinct fates, one a stem cell and one a differentiating cell, as well as the functions of satellite DNA, which she found to be crucial, unlike the waste they were previously thought to be.

Yamashita received her bachelors degree in biology in 1994 and her PhD in biophysics in 1999, both from Kyoto University. After being a postdoc at Stanford University for five years, she was appointed a faculty member at the University of Michigan in 2007. She joined the Department of Biology as a full professor with a July 1 start. She also became a member of the Whitehead Institute of Biomedical Research and is a standing investigator at the Howard Hughes Medical Institute.

The rest is here:
School of Science grows by 10 - MIT News

Faculty of Medicine researchers receive $2.8m for equipment and infrastructure – UBC Faculty of Medicine – UBC Faculty of Medicine

By Stephanie Chow | September 8, 2020

Eleven Faculty of Medicine researchers have received a combined $2.8 million for state-of-the-art labs and equipment.

The funding comes from the Government of Canada, through the Canada Foundation for Innovations (CFI) John R. Evans Leaders Fund. The investment provides researchers with the highly specialized infrastructure they need to be leaders in their field.

Deciphering DNA-encoded Gene-regulatory Logic with Genome-scale Synthetic DNA Carl de Boer, School of Biomedical Engineering

Infrastructure for Developing Pharmacologic Approaches to Modulating Fibrinolysis and Controlling Bleeding Disorders Christian Kastrup, Michael Smith Laboratories

Stem Cell and Genome Editing Lab Timothy Kieffer, Department of Cellular & Physiological Sciences

Community Hub for Arts-based Research and Innovation in Knowledge Translation Andrea Krusi, School of Population and Public Health

Exploring Mitochondria Function as Therapeutic Target in Acute Myeloid Leukemia and Multiple Myeloma Florian Kuchenbauer, Department of Medical Genetics

Hapscreen-RD: A Platform for Large-scale Screening of Human Haploid Cells for Rare Disease Research Josef Penninger, Life Sciences Institute & Department of Medical Genetics

Innovation in Mobility and Balance Rehabilitation Courtney Pollock, Department of Physical Therapy

The Stroke Management and eHealth Innovation Laboratory Brodie Sakakibara, Department of Occupational Science and Occupational Therapy, Southern Medical Program

Cryo-EM of Metabolic Enzymes for Drug Discovery Sriram Subramaniam, Department of Biochemistry

Investigating How Mitochondrial Stress Signaling Maintains Organelle Homeostasis in Health and Disease Hilla Weidberg, Department of Cellular & Physiological Sciences

Investigating the Neurophysiological Effects and Accumulation of Subconcussive Sports Head Impacts Lyndia Chun Wu, School of Biomedical Engineering

See the rest here:
Faculty of Medicine researchers receive $2.8m for equipment and infrastructure - UBC Faculty of Medicine - UBC Faculty of Medicine

BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia…

September 08, 2020 07:00 ET | Source: BeyondSpring, Inc.

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) -

- Designation Based on PROTECTIVE-2 Phase 3 Interim Data, Reinforcing Significant Treatment Need in CIN -

- Among the First Three Innovative Drugs to Receive Breakthrough Therapy Designations in China -

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that its lead asset, first-in-class agent Plinabulin, has received the Breakthrough Therapy Designation (BTD) for the chemotherapy-induced neutropenia (CIN) indication from both the U.S. Food and Drug Administration (FDA) and Chinas Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

The FDA's BTD is intended to expedite the development and review of a drug candidate that is planned to treat a serious or life-threatening disease or condition in which clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.The CDE in China established its BTD program in July 2020 to facilitate the research and development of innovative drugs that treat severe life-threatening or quality-of-life impairing diseases with no existing therapy or with proven evidence to demonstrate clear clinical benefits compared to existing therapies. Products with BTD from the CDE may be considered for conditional approval and priority review when submitting New Drug Applications (NDAs).

"Receipt of Breakthrough Therapy Designation from the FDA acknowledges both the significant unmet need among patients with CIN and the highly encouraging clinical results generated by Plinabulin, said Douglas Blayney, M.D., global Principal Investigator for Plinabulins CIN studies and Professor of Medicine at the Stanford University School of Medicine. This should expedite Plinabulins move into the clinic, which is beneficial for patients. The currently approved CIN prevention agents are all G-CSF-based and not available to all patients. Even with the use of G-CSFs, over 80 percent of cancer patients undergoing chemotherapy may still experience Grade 4 neutropenia, which could lead to severe infection, hospitalization and even death. Thus, CIN still represents an unmet medical need.

"The clinical profile Plinabulin has shown truly represents a breakthrough in the CIN space since G-CSFs," added Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President, Research and Development, at BeyondSpring. We look forward to continuing to work with the FDA as we advance the development of Plinabulin to address this urgent medical need.

The Breakthrough Therapy application is based on the strength of the totality of the clinical data generated so far:

The Company expects to report the full PROTECTIVE-2 Phase 3 topline data in Q4 2020 and file an NDA with the FDA by the end of 2020. The Company has submitted an NDA for Plinabulin for the CIN indication to the NMPA on a rolling basis in Q1 2020.

About Chemotherapy-Induced Neutropenia (CIN) CIN is a common side effect in cancer patients undergoing treatment that involves the destruction of a type of white blood cell, the neutrophil, which is a patients first line of defense against infections. Patients with Grade 4 (severe) neutropenia have an abnormally low concentration of neutrophils, which may lead to infections, hospitalization and death.

G-CSFs are the current standard of care for CIN prevention. However, G-CSFs have limitations in reducing Grade 4 neutropenia with high-risk chemotherapy. Neutropenia, if severe enough, may cause doctors to lower target doses of chemotherapy, end therapy early and / or delay chemotherapy cycles, each of which has a negative effect on long-term outcomes of cancer care.

Despite these limitations annual global use of G-CSFs is more than 4.3 million cycles per year (CPY). The U.S. (1.3 million CPY) and China (1.6 million CPY) account for more than two-thirds of the global CIN market. Plinabulins demonstrated clinical profile in combination with G-CSFs has the potential to build on this existing base and improve the standard of care for patients and practitioners.

About Plinabulin Plinabulin, BeyondSprings lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

About Plinabulin in CIN Study The PROTECTIVE-1 (Study 105) and PROTECTIVE-2 (Study 106) trials are both multicenter, double-blind, active controlled Phase 3 trials to support Plinabulins broad application in preventing CIN: Plinabulin for concurrent administration with myelosuppressive chemotherapy regimens in patients with non-myeloid malignancies for the presentation of chemotherapy-induced neutropenia (CIN).

PROTECTIVE-1 (Study 105)This study was designed to evaluate the safety and efficacy in non-small cell lung cancer (NSCLC), breast cancer and prostate cancer patients with risk factors, treated with docetaxel (Day 1 dose) in a 21-day cycle with a single dose of Plinabulin (40mg, Day 1 dose) versus a single dose of Neulasta (6mg, Day 2). Docetaxel is one example of an intermediate-risk chemotherapy. This is a non-inferiority study in CIN efficacy comparing Plinabulin and Neulasta in high-risk patients (intermediate chemotherapy, plus one or more additional risk factor). Study 105 Phase 3 interim data had achieved statistical significance based on the primary endpoint of the Duration of Severe Neutropenia (DSN) in the first cycle.

PROTECTIVE-2 (Study 106)This study was designed to evaluate the safety and efficacy in breast cancer, treated with docetaxel, doxorubicin and cyclophosphamide (TAC, Day 1 dose) in a 21-day cycle with Plinabulin (40 mg, Day 1 dose) in combination with Neulasta (6 mg, Day 2 dose) versus a single dose of Neulasta (6 mg, Day 2 dose) alone. TAC is an example of high-risk chemotherapy. Plinabulin and G-CSFs have complementary mechanisms in preventing chemotherapy-induced neutropenia (CIN). This is a superiority study in CIN efficacy in the rate of Grade 4 neutropenia prevention (primary endpoint), comparing the combination head-to-head against Neulasta, and is currently enrolling. Literature shows that the Grade 4 neutropenia rate for TAC and Neulasta at 6 mg is 83 to 93 percent, which presents severe unmet medical needs.

Covance is the clinical contract research organization (CRO) for patient recruitment and monitoring of global sites for this study. The CIN studies are conducted in over 60 clinical centers in the U.S., China and Europe. In addition, Absolute Neutrophil Count (ANC) data, which is used to calculate these endpoints, was obtained through central laboratory assessments by Covance Bioanalytical Methods using standardized and validated analytical tests.

About BeyondSpring Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSprings first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen doses decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a pipeline drug, Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed molecular glue that uses the protein degradation pathway.

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSprings most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com

Read more from the original source:
BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia...